RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
RAPT Therapeutics - Stock

RAPT Therapeutics Stocks 2024

RAPT Therapeutics Stocks

38.34 M

Ticker

RAPT

ISIN

US75382E1091

WKN

A2PNYQ

In 2024, RAPT Therapeutics had 38.34 M outstanding stocks, a 0% change from the 38.34 M stocks in the previous year.

The RAPT Therapeutics Stocks history

YEARNUMBER OF STOCKS (undefined USD)
2029e38.34
2028e38.34
2027e38.34
2026e38.34
2025e38.34
2024e38.34
202338.34
202232.54
202127.39
202024.13
201922.75
201822.75
201722.75

RAPT Therapeutics shares outstanding

The number of shares was RAPT Therapeutics in 2023 — This indicates how many shares 38.338 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue RAPT Therapeutics earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates RAPT Therapeutics's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of RAPT Therapeutics’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating RAPT Therapeutics's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

RAPT Therapeutics Aktienanalyse

What does RAPT Therapeutics do?

Rapt Therapeutics Inc. is an emerging pharmaceutical company that was originally founded in 2015 under the name "FLX Bio". The company is based in San Francisco, California. Rapt is the name of the biological process that the company uses to identify and develop drug candidates. Rapt Therapeutics specializes in developing innovative immunotherapies for cancer treatment. The goal is to harness the power of the immune system to support the body in fighting cancer. The company focuses on developing prophylactic cancer vaccines and immunotherapies that aim to directly combat cancer cells and strengthen the body's defenses. The company's business model is based on an innovative technology platform that is able to identify antibodies and other molecules that activate the RAPT process, which is important for combating cancer cells. With this technology, Rapt Therapeutics can quickly and accurately identify potential drug candidates that are suitable for the development of cancer immunotherapies. At the time of its founding, Rapt primarily focused on developing immunotherapeutics for solid tumors, a type of cancer that originates in a specific tissue in the body and does not spread to adjacent tissues or organs. However, the company has since expanded its portfolio to include the development of therapeutics for hematological cancers such as leukemia and lymphoma. Rapt Therapeutics employs a pipeline-based research strategy. The pipeline-based research strategy means that Rapt Therapeutics develops a variety of drug candidates targeting different disease indications. The drug candidates are then tested in different phases of clinical development to evaluate their efficacy and safety. To date, Rapt Therapeutics has four drug candidates in clinical development. The first candidate, RPT193, is currently being tested in phase 1 clinical trials for the treatment of various solid tumors. The second candidate, RPT835, is currently in preclinical development and targets the treatment of leukemia. The third candidate, FLX475, is also in preclinical development and targets the treatment of multiple sclerosis. The fourth candidate, FLX475, is currently in phase 1 clinical trials and targets the treatment of certain solid tumors. In addition, Rapt Therapeutics has also entered into a number of partnerships with other pharmaceutical companies. In 2018, Rapt Therapeutics signed a strategic collaboration with AstraZeneca to accelerate the development of RPT193. Under this collaboration, AstraZeneca will test RPT193 in clinical trials. In 2019, Rapt Therapeutics entered into a research and development collaboration with Hanmi Pharmaceutical Co. Ltd. to accelerate the discovery, development, and commercialization of drug candidates for cancer and other diseases. Rapt Therapeutics is pursuing a long-term strategy to become a leading company in immunotherapy development. By continuing its research and development of cancer immunotherapies, Rapt has the potential to improve the lives of millions of people suffering from cancer and other serious diseases. RAPT Therapeutics ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating RAPT Therapeutics's Shares Outstanding

RAPT Therapeutics's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in RAPT Therapeutics’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding RAPT Therapeutics’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in RAPT Therapeutics’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about RAPT Therapeutics stock

How many stocks are there of RAPT Therapeutics?

The current number of stocks of RAPT Therapeutics is 38.34 M undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of RAPT Therapeutics are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of RAPT Therapeutics evolved in recent years?

The number of shares of RAPT Therapeutics has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. RAPT Therapeutics as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of RAPT Therapeutics?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does RAPT Therapeutics pay?

Over the past 12 months, RAPT Therapeutics paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, RAPT Therapeutics is expected to pay a dividend of 0 USD.

What is the dividend yield of RAPT Therapeutics?

The current dividend yield of RAPT Therapeutics is .

When does RAPT Therapeutics pay dividends?

RAPT Therapeutics pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of RAPT Therapeutics?

RAPT Therapeutics paid dividends every year for the past 0 years.

What is the dividend of RAPT Therapeutics?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is RAPT Therapeutics located?

RAPT Therapeutics is assigned to the 'Health' sector.

Wann musste ich die Aktien von RAPT Therapeutics kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of RAPT Therapeutics from 7/7/2024 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 7/7/2024.

When did RAPT Therapeutics pay the last dividend?

The last dividend was paid out on 7/7/2024.

What was the dividend of RAPT Therapeutics in the year 2023?

In the year 2023, RAPT Therapeutics distributed 0 USD as dividends.

In which currency does RAPT Therapeutics pay out the dividend?

The dividends of RAPT Therapeutics are distributed in USD.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

The RAPT Therapeutics stock can be added to a savings plan with the following providers: Trade Republic

Andere Kennzahlen von RAPT Therapeutics

Our stock analysis for RAPT Therapeutics Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of RAPT Therapeutics Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.